|
Richard J. Wallace has served as a director of Avigen, Inc., a publicly-traded biopharmaceutical company focused on unique small molecule therapeutics and biologics to treat serious neurological disorders, since March 2006. Mr. Wallace is also a Senior Vice President in Research and Development at GlaxoSmithKline (GSK). During fifteen years at GSK, Mr. Wallace has performed a number of roles from Vice President Commercial (Canada), Vice President US Business Development, Vice President Sales and Marketing (US Oncology and HIV), Vice President Global Clinical Development and Product Strategy (Neurosciences) and most recently, Senior Vice President Global Product Strategy for all therapeutic areas in the GSK portfolio. Mr. Wallace’s experience prior to joining GSK included eight (8) years with Bristol Myers Squibb and seven (7) years at Johnson & Johnson (in assignments spanning marketing, sales, manufacturing and general management). Mr. Wallace received B. Commerce and B. Com. Honors degrees from Rhodes University, South Africa. | 